Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Asthma Β· Type 2 Diabetes

AstraZeneca

AstraZeneca clinical programs β€” 129 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
129
Drugs
77
Patents
25
Official website β†— All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis β†’
Intelligence Β· Clinical Programs

AstraZeneca projects

129 ClinicalTrials.gov programs sponsored by AstraZeneca.

AstraZeneca has 129 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

129 programs

Clinical programs

Page 3 of 3

  1. AZD6793

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  2. AZD8931

    AstraZeneca

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  3. AZD9668

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  4. Atuliflapon

    AstraZeneca

    Asthma

    phase 2 small molecule completed

    1 trial

  5. Calquence 100 mg film-coated tablets

    AstraZeneca

    mantle cell lymphoma (MCL)

    phase 2 small molecule active

    1 trial

  6. D6405C00002

    AstraZeneca

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  7. Fostamatinib

    AstraZeneca

    Rheumatoid Arthritis

    phase 2 small molecule terminated

    1 trial

  8. Gefitinib

    AstraZeneca

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  9. MEDI4736

    AstraZeneca

    Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule completed

    1 trial

  10. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  11. Osimertinib + Savolitinib

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Osimertinib 80 mg/40 mg

    AstraZeneca

    Stage II-IIIB Non-small Cell Lung Carcinoma

    phase 2 small molecule active

    1 trial

  13. Tozorakimab

    AstraZeneca

    Asthma

    phase 2 small molecule active

    1 trial

  14. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial

  15. Volrustomig

    AstraZeneca

    Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

    phase 2 mab active

    1 trial

  16. osimertinib

    AstraZeneca

    Carcinoma

    phase 2 small molecule active

    1 trial

  17. AZD0449

    AstraZeneca

    Asthma

    phase 1 small molecule completed

    1 trial

  18. AZD0530

    AstraZeneca

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  19. AZD3514

    AstraZeneca

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  20. AZD6244

    AstraZeneca

    Neoplasms,

    phase 1 small molecule completed

    1 trial

  21. AZD7762

    AstraZeneca

    Cancer

    phase 1 small molecule terminated

    1 trial

  22. Benralizumab

    AstraZeneca

    Healthy Subjects

    phase 1 mab completed

    1 trial

  23. Capivasertib

    AstraZeneca

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  24. Ceralasertib

    AstraZeneca

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  25. Cisplatin

    AstraZeneca

    Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

    phase 1 small molecule terminated

    1 trial

  26. Drug-AZD8931

    AstraZeneca

    Breast Neoplasm

    phase 1 small molecule terminated

    1 trial

  27. Sodium Zirconium Cyclosilicate (ZS)

    AstraZeneca

    Hyperkalemia

    phase 1 small molecule completed

    1 trial

  28. AZD1222

    AstraZeneca

    COVID-19, SARS-CoV-2

    approved mab terminated

    1 trial

  29. D9311L00001

    AstraZeneca

    Advanced or recurrent endometrial cancer

    approved small molecule active

    1 trial

  30. Dapagliflozin

    AstraZeneca

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  31. Durvalumab

    AstraZeneca

    Solid Tumor

    approved small molecule completed

    1 trial

  32. Symbicort Turbuhaler (budesonide/formoterol) 320/9 ΞΌg

    AstraZeneca

    Chronic Obstructive Pulmonary Disease (COPD)

    approved small molecule completed

    1 trial

  33. Symbicort Turbuhaler 160/4.5

    AstraZeneca

    Asthma

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does AstraZeneca have?

129 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.